FDA Approves Litfulo: Key Facts on Pfizer’s Alopecia Treatment
The FDA has approved Litfulo, a groundbreaking treatment by Pfizer for alopecia, offering new hope for individuals struggling with hair loss.
The FDA approved Litfulo (ritlecitinib) on June 23, 2023, making it the first and only treatment for severe alopecia areata in adolescents and adults aged 12 and older. The oral JAK3 inhibitor offers a new option for patients with 50% or more scalp hair loss.
Contents10 sections
Key Takeaways
- FDA approved Litfulo (ritlecitinib) on June 23, 2023, under NDA 215830 for severe alopecia areata in patients aged 12+ [FDA Approval Letter]
- ALLEGRO Phase 2b/3 trial showed 31% of patients achieved 80% or more scalp hair coverage at week 24 versus 2% with placebo [PubMed]
- Recommended dose is 50 mg once daily; the drug is the first approved specifically for adolescents with this condition
- Safety profile includes class-typical JAK inhibitor risks: infections, elevated liver enzymes, and lipid abnormalities
What Is Litfulo?
Litfulo (ritlecitinib) is a selective oral kinase inhibitor developed by Pfizer. It targets Janus kinase 3 (JAK3) and members of the TEC kinase family, blocking signaling pathways that drive the autoimmune attack on hair follicles in alopecia areata. The drug received FDA approval on June 23, 2023, following a priority review [Pfizer].
Who Can Take Litfulo?
The approved indication covers adults and adolescents aged 12 years and older with severe alopecia areata, defined as 50% or more scalp hair loss. This population previously had limited FDA-approved systemic treatment options. The approval makes ritlecitinib the first and only treatment specifically approved for adolescents with this condition [FDA].
What Did the ALLEGRO Clinical Trial Show?
The approval was based on results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial (NCT03732807). The study enrolled 718 patients aged 12 and older across 118 sites in 18 countries [ClinicalTrials.gov].
The primary endpoint was the proportion of patients achieving a Severity of Alopecia Tool (SALT) score of 20 or less at week 24, indicating 80% or more scalp hair coverage. Results showed:
- 31% of patients in the 200 mg loading dose / 50 mg maintenance group achieved SALT ≤20 vs. 2% with placebo
- 23% of patients in the 50 mg group achieved SALT ≤20 at week 24
- Response rates continued to improve through week 48, with 34-55% achieving SALT50
- Improvements were seen across scalp, eyebrow, and eyelash hair regrowth
The study was published in The Lancet in 2023 [PubMed].
How Is Litfulo Dosed?
The recommended dosage is 50 mg taken orally once daily, with or without food. No loading dose is required for the approved regimen. Patients should take the medication consistently at the same time each day. If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose.
What Are the Side Effects?
In clinical trials, ritlecitinib demonstrated an acceptable safety profile over 48 weeks. The most common adverse events included:
- Upper respiratory tract infections
- Nasopharyngitis
- Headache
- Diarrhea
- Acne
- Rash and urticaria
As a JAK inhibitor, Litfulo carries class-specific warnings including increased risk of serious infections, elevated liver enzymes, elevated lipid levels, and potential thromboembolic events. Monitoring is recommended during treatment. No deaths or major safety signals were reported in the Phase 2b/3 trial.
How Does Litfulo Compare to Other Treatments?
Litfulo is the first FDA-approved JAK inhibitor specifically for adolescents with alopecia areata. Other JAK inhibitors approved for alopecia areata include baricitinib (Olumiant) and ruxolitinib (Opzelura), though these have approvals primarily in adults. Prior to JAK inhibitors, treatment options were limited to corticosteroids and off-label immunomodulators.
| Drug | Developer | Approval Date | Age Group |
|---|---|---|---|
| Litfulo (ritlecitinib) | Pfizer | June 2023 | 12+ years |
| Olumiant (baricitinib) | Eli Lilly | June 2022 | Adults |
| Opzelura (ruxolitinib) | Incyte | July 2023 | Adults |
What Is the Market Impact?
The approval addresses a significant unmet need for adolescents with moderate to severe alopecia areata. Pfizer estimates thousands of patients in the United States could benefit from this targeted therapy. The drug represents a shift from corticosteroid-based treatments to targeted kinase inhibition.
Frequently Asked Questions
When was Litfulo approved by the FDA?
The FDA approved Litfulo (ritlecitinib) on June 23, 2023, for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older [FDA Approval Letter].
What is the recommended dosage of Litfulo?
The recommended dose of Litfulo is 50 mg taken once daily, with or without food. No loading dose is required for the approved regimen.
What were the results of the ALLEGRO clinical trial?
In the ALLEGRO Phase 2b/3 trial (NCT03732807), 31% of patients receiving ritlecitinib 200 mg loading dose followed by 50 mg achieved a SALT score of 20 or less at week 24, compared to 2% with placebo. Response rates continued to improve through week 48 [PubMed].
What are the most common side effects of Litfulo?
The most common adverse events in clinical trials included upper respiratory tract infections, nasopharyngitis, headache, diarrhea, acne, rash, and urticaria. Most were mild to moderate in severity. Class-specific warnings include infections, liver enzyme elevations, and lipid abnormalities.
Primary Sources
- FDA Approval Letter for Litfulo (ritlecitinib). NDA 215830. Approved June 23, 2023.
- Pfizer Press Release: FDA Approves Pfizer's LITFULO™ (Ritlecitinib). June 23, 2023.
- King B, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518-1529.
- ClinicalTrials.gov: ALLEGRO Phase 2b/3 Trial NCT03732807. Study record for ritlecitinib in alopecia areata.
Continue Exploring
Jump into the entities behind this story.
Follow ritlecitinib developments
FDA alopecia areata alerts and ritlecitinib pipeline updates, every Monday.
This article follows our editorial standards. Report a correction via editorial contact.
